Market capitalization | $3.78b |
Enterprise Value | $7.49b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 32.64 |
EV/Sales (TTM) EV/Sales | 1.69 |
P/S ratio (TTM) P/S ratio | 0.85 |
P/B ratio (TTM) P/B ratio | 0.83 |
Dividend yield | 3.94% |
Last dividend (FY23) | $1.09 |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
6 Analysts have issued a Perrigo Company forecast:
6 Analysts have issued a Perrigo Company forecast:
Jun '24 |
+/-
%
|
||
Revenue | 4,429 4,429 |
4%
4%
|
|
Gross Profit | 1,591 1,591 |
0%
0%
|
|
EBITDA | 597 597 |
2%
2%
|
EBIT (Operating Income) EBIT | 256 256 |
20%
20%
|
Net Profit | -119 -119 |
78%
78%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Perrigo Co. Plc is a healthcare company, which engages in the production of over-the-counter consumer goods and specialty pharmaceutical products. It operates through the following segments: Consumer Self-Care Americas, Consumer Self-Care International, and Prescription Pharmaceuticals. The Consumer Self-Care Americas segment comprises the U.S., Mexico and Canada consumer healthcare business. The Consumer Self-Care International segment includes branded consumer healthcare business primarily in Europe and consumer focused businesses in the U.K., Australia, and Israel. The Prescription Pharmaceuticals refers to the U.S. prescription pharmaceuticals business. The company was founded by Luther Perrigo in 1887 and is headquartered in Dublin, Ireland.
Head office | United States |
CEO | Patrick Lockwood-Taylor |
Employees | 9,140 |
Founded | 1887 |
Website | www.perrigo.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.